DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
8.04
-0.43 (-5.08%)
At close: Jan 30, 2026, 4:00 PM EST
8.36
+0.32 (3.98%)
After-hours: Jan 30, 2026, 7:11 PM EST

DiaMedica Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
9.227.628.166.164.884.49
Research & Development
24.3919.0613.117.848.778.21
Operating Expenses
33.626.6821.271413.6512.7
Operating Income
-33.6-26.68-21.27-14-13.65-12.7
Interest & Investment Income
2.272.271.930.35--
Other Non Operating Income (Expenses)
-0.56---0.080.43
EBT Excluding Unusual Items
-31.9-24.41-19.34-13.65-13.56-12.27
Pretax Income
-31.9-24.41-19.34-13.65-13.56-12.27
Income Tax Expense
0.030.030.040.030.030.03
Net Income
-31.93-24.44-19.38-13.68-13.59-12.29
Net Income to Common
-31.93-24.44-19.38-13.68-13.59-12.29
Shares Outstanding (Basic)
454033262116
Shares Outstanding (Diluted)
454033262116
Shares Change (YoY)
13.70%24.07%23.16%27.29%32.48%30.80%
EPS (Basic)
-0.72-0.60-0.60-0.52-0.65-0.78
EPS (Diluted)
-0.72-0.60-0.60-0.52-0.65-0.78
Free Cash Flow
-27.77-22.1-18.75-11.59-12.27-9.23
Free Cash Flow Per Share
-0.62-0.55-0.58-0.44-0.59-0.59
EBITDA
-33.56-26.64-21.24-13.98-13.62-12.68
D&A For EBITDA
0.040.040.030.030.020.02
EBIT
-33.6-26.68-21.27-14-13.65-12.7
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q